Hedgehog- and mTOR-targeted therapies for advanced basal cell carcinomas. (November 2015)

• Record Type: Journal Article
• Authors: Piérard-Franchimont, Claudine; Hermanns-Lê, Trinh; Paquet, Philippe; Herfs, Michael; Delvenne, Philippe; Piérard, Gérald E
• Is Part Of: Future oncology. Volume 11:Number 22(2015)
• Page Start: 2997
• Page End: 3002
• Publication Date: 2015-11
• Subjects: basal cell carcinoma -- cancer stem cell -- cyclopamine -- cytotoxic chemotherapy -- Desert Hedgehog -- EGF -- everolimus -- Hedgehog -- hereditary basal cell nevus syndrome -- Indian Hedgehog -- itraconazole -- metastasis -- NF-κB -- protein kinase -- PTCH1 -- SMO -- Sonic Hedgehog -- TGF -- therapy resistance -- vismodegib; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon.15.181
• Languages: English
• ISSNs: 1479-6694

Abstract

Basal cell carcinomas (BCCs) are the most frequent human cancer. Over 90% of all BCCs have a mutation in PTCH1 or smoothened, two conducting proteins of the Hedgehog pathway. They rarely progress deeply and metastasize; however, if they do, these advanced basal cell carcinoma become amenable to treatment by inhibiting the Hedgehog and the P13K–mTOR pathways. Such innovative drugs include vismodegib, cyclopamine, itraconazole, everolimus and a few other agents that are in early clinical development.